Guochuan Emil Tsai

This inventor holds 36 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Syneurx International (Taiwan) Corp., Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center, Synenrx International (Taiwan) Corp.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guochuan Emil Tsai. Retrieved from https://idiyas.com/inventor/guochuan-emil-tsai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 36 (Patent Applications = 6)

% Patents Active = 97.2

CIPO Patents = 2 (Patent Applications = 11)

EPO Patents = 8 (Patent Applications = 15)

Average Co-Inventor Count = 2.8

ph-index = 5

Forward Citations = 61(Granted Patents)

Company Filing History:

30 out of 31

Syneurx International (Taiwan) Corp.

patents

5 out of 95

Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center

patents

1 out of 1

Synenrx International (Taiwan) Corp.

patent

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

Pharmaceutical Uses

Cycloserine Compounds

D-Amino Acid Oxidase

Co-Crystals

Lithium Salts

Benzoate Compounds

Tannic Acid

Neuropharmaceuticals

Polymorphic Forms

Central Nervous System

Sorbic Acid

Therapeutic Applications

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12714711 - Salts of neuroceuticals and uses thereof (2026-08-25),

2. 12521410 - Compounds and pharmaceutical uses thereof (2026-01-13),

3. 12178804 - Salts of cycloserine compounds and applications thereof (2024-12-31),

4. 11793823 - Compounds and pharmaceutical uses thereof (2023-10-24),

5. 11779561 - Compounds and pharmaceutical uses thereof (2023-10-10),

6. 11753400 - D-amino acid oxidase inhibitors and therapeutic uses thereof (2023-09-12),

7. 11739046 - Co-crystals of lithium benzoate and uses thereof (2023-08-29),

8. 11731928 - Co-crystals of sodium benzoate and uses thereof (2023-08-22),

9. 11529342 - Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical (2022-12-20),

10. 11382924 - Compounds and pharmaceutical uses thereof (2022-07-12),

11. 11369579 - Polymorphic forms of sodium benzoate and uses thereof (2022-06-28),

12. 11291654 - Formulations of cycloserine compounds and applications thereof (2022-04-05),

13. 11278509 - Lithium salts of N-substituted glycine compounds and uses thereof (2022-03-22),

14. 11202791 - Compositions containing tannic acids and uses thereof (2021-12-21),

15. 11154531 - Compounds and pharmaceutical uses thereof (2021-10-26),

Title: Innovations of Guochuan Emil Tsai: A Trailblazer in Pharmaceutical Patents

Introduction: Guochuan Emil Tsai, located in Pasadena, California, is an esteemed inventor with a remarkable portfolio of 34 patents. His contributions to the field of pharmaceutical compounds focus on advancements that enhance stability and therapeutic efficacy.

Latest Patents: Among his latest innovations, Tsai has developed salts of cycloserine compounds and their applications. This innovation introduces salts characterized by the formula [A][B], where [A] represents a cation form of a cycloserine compound and [B] is an anion from a specified compound. These salts exhibit significantly improved properties, such as increased stability and decreased hygroscopicity. Furthermore, Tsai has provided methods for treating and reducing the risk of neuropsychiatric disorders and bacterial infections, including tuberculosis, through the administration of these compositions. Additionally, he has patented a compound of Formula (I), featuring a range of therapeutic uses, emphasizing its potential in advanced pharmaceutical applications.

Career Highlights: Tsai has worked with prominent institutions such as Syneurx International Corp. and the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. His expertise and innovative spirit have made substantial contributions to pharmaceutical research and development.

Collaborations: Throughout his career, Guochuan Emil Tsai has collaborated with notable colleagues such as Ching-Cheng Wang and Tien-Lan Hsieh. These collaborations have led to significant advancements in the therapeutic applications of his patented compounds.

Conclusion: Guochuan Emil Tsai stands out as a pioneering inventor in the pharmaceutical field, with a strong emphasis on enhancing compound stability and therapeutic potential. His continued work and dedication to innovation remain pivotal in advancing medical treatments and improving patient outcomes.

Profile summary based on public USPTO records.